Shana Carol Neal, Executive Vice President and Chief People Officer at Becton Dickinson & Co (NYSE:BDX), recently sold 1,000 shares of the company's common stock. The shares were sold on December 6, 2024, at a weighted average price of $220.49, amounting to a total transaction value of $220,490. The sale was executed under a Rule 10b5-1 trading plan, which Neal adopted on September 6, 2024. Following this transaction, Neal retains ownership of 16,989 shares in the medical technology company. The sale prices for the transactions ranged from $219.41 to $221.50. Trading near its 52-week low with a 1.88% dividend yield and a 54-year history of consecutive dividend increases, BDX maintains relatively low price volatility. Get comprehensive insider trading analysis and 10+ additional ProTips with InvestingPro.
In other recent news, Becton Dickinson (BD), a global medical technology company, disclosed strong financial results in its Fourth Quarter and Full-Year Fiscal 2024 Earnings Call. The company reported a 7.4% Q4 revenue growth and a full-year organic revenue increase of 5%. Additionally, BD's adjusted diluted earnings per share (EPS) rose by 11.4%, reaching $13.14 for the full year. Despite challenges in China and the Bioscience-Pharma sector, the MedTech and Diagnostics segments exhibited growth by 5.9%, with BD Medical (TASE:PMCN)'s biologic drug delivery sales exceeding $1 billion.
In other recent developments, BD announced a $1 billion share repurchase plan and increased its dividend by 9.5%. The company expects high single-digit revenue growth for FY '25, with a cautious outlook on the Chinese market due to value-based procurement pressures. However, BD remains optimistic about innovations in biologics and diagnostics, as well as the integration of the Advanced Patient Monitoring business, driving growth. The company also anticipates a stronger second half of FY '25 and a 100 basis point increase in operating margins.
While BD expects a mid-single-digit decline in China and a modest Q1 performance, the company maintains a positive outlook for key products such as Alaris and the continued growth of the MedTech and Diagnostics segments. Finally, the company's management has outlined capital allocation strategies, including R&D investment for the integration of Advanced Patient Monitoring, as part of their fiscal year 2025 plan.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.